InMed closes C$5.8M follow-on

Cannabinoid-based therapeutics developer InMed Pharmaceuticals Inc. (CNSX:IN; OTCQB:IMLFF) raised C$5.8 million ($4.3 million) through the sale of 12.8 million units at C$0.45 in a follow-on underwritten by Canaccord Genuity, Eight Capital and Roth Capital Partners...